NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

Authors :: Liu J
Berchuck A
Backes FJ
Cohen J
Grisham R
Leath CA
Martin L
Matei D
Miller DS
Robertson S
Barroilhet L
Uppal S
Hendrickson AW
Gershenson DM
Gray HJ
Hakam A
Jain A
Konecny GE
Moroney J
Ratner E
Schorge J
Thaker PH
Werner TL
Zsiros E
Behbakht K
Chen LM
DeRosa M
Eisenhauer EL
Leiserowitz G
Litkouhi B
McHale M
Percac-Lima S
Rodabaugh K
Vargas R
Jones F
Kovach E
Hang L
Ramakrishnan S
Alvarez RD
Armstrong DK
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Oct; Vol. 22 (8), pp. 512-519.
Publication Year :: 2024
Abstract: The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

Subjects :: Humans
Female
Medical Oncology standards
Medical Oncology methods
Neoplasm Staging
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
Ovarian Neoplasms diagnosis
Ovarian Neoplasms therapy
Ovarian Neoplasms pathology
Peritoneal Neoplasms therapy
Peritoneal Neoplasms diagnosis
Fallopian Tube Neoplasms diagnosis
Fallopian Tube Neoplasms therapy
Fallopian Tube Neoplasms pathology

Full Text Access

Tools